

# Corinne Faivre-Finn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/295596/publications.pdf>

Version: 2024-02-01

243  
papers

18,950  
citations

23544

58  
h-index

12933

131  
g-index

249  
all docs

249  
docs citations

249  
times ranked

16919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 265-270.	0.4	1
2	Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 104-114.	5.1	123
3	Evaluation of Prognostic and Predictive Models in the Oncology Clinic. <i>Clinical Oncology</i> , 2022, 34, 102-113.	0.6	9
4	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
5	Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 197-199.	0.5	6
6	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	0.9	7
7	Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study. <i>PLoS Medicine</i> , 2022, 19, e1003904.	3.9	28
8	Radial Data Mining to Identify Density-Dose Interactions That Predict Distant Failure Following SABR. <i>Frontiers in Oncology</i> , 2022, 12, 838155.	1.3	2
9	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	0.9	5
10	Understanding the Differences Between Bayesian and Frequentist Statistics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1076-1082.	0.4	24
11	Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, e325-e329.	1.1	3
12	Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020. <i>Radiotherapy and Oncology</i> , 2022, 172, 118-125.	0.3	12
13	Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 172, 126-133.	0.3	7
14	Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey. <i>Lung Cancer</i> , 2022, 169, 94-101.	0.9	6
15	Unaccounted Confounders Limit the Ability to Draw Conclusions From Big Data Analysis Comparing Radiotherapy Fractionation Regimens in NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, e55-e56.	0.5	0
16	Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. <i>Journal of Thoracic Oncology</i> , 2022, 17, 961-973.	0.5	9
17	Role of radiotherapy in the management of brain metastases of NSCLC – Decision criteria in clinical routine. <i>Radiotherapy and Oncology</i> , 2021, 154, 269-273.	0.3	11
18	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30

#	ARTICLE	IF	CITATIONS
19	Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1341-1348.	0.4	17
20	Automated gross tumor volume contour generation for large-scale analysis of early-stage lung cancer patients planned with 4D-CT. <i>Medical Physics</i> , 2021, 48, 724-732.	1.6	4
21	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	0.9	11
22	Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 617681.	1.3	26
23	Thoracic radiotherapy in small cell lung cancer—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2059-2070.	1.3	14
24	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	1.3	8
25	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184.	1.1	2
26	Optimising use of 4D-CT phase information for radiomics analysis in lung cancer patients treated with stereotactic body radiotherapy. <i>Physics in Medicine and Biology</i> , 2021, 66, 115012.	1.6	8
27	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	0.5	323
28	MRI and CBCT for lymph node identification and registration in patients with NSCLC undergoing radical radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 159, 112-118.	0.3	7
29	Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer. <i>Lancet Oncology</i> , The, 2021, 22, e220.	5.1	1
30	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.3	11
31	Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1075-1085.	0.5	19
32	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 867-875.	0.4	37
33	Outcomes of curative-intent radiotherapy in non-small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). <i>Radiotherapy and Oncology</i> , 2021, 160, 78-81.	0.3	9
34	The Routine Clinical Implementation of Electronic Patient-reported Outcome Measures (ePROMs) at The Christie NHS Foundation Trust. <i>Clinical Oncology</i> , 2021, 33, 761-764.	0.6	18
35	Excess deaths from COVID-19 and other causes by region, neighbourhood deprivation level and place of death during the first 30 weeks of the pandemic in England and Wales: A retrospective registry study. <i>Lancet Regional Health - Europe</i> , The, 2021, 7, 100144.	3.0	35
36	Role of Postoperative Radiotherapy in the Management for Resected NSCLC – Decision Criteria in Clinical Routine Pre- and Post-LungART. <i>Clinical Lung Cancer</i> , 2021, 22, 579-586.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Small-cell lung cancer. Nature Reviews Disease Primers, 2021, 7, 3.	18.1	560
38	Cancers bronchiques de stade III : rôle de l'immunothérapie onco-radiothérapeutique. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S97-2S108.	0.0	0
39	Prise en charge des cancers bronchiques non à petites cellules oligométastatiques. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S109-2S120.	0.0	0
40	Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC. International Journal of Radiation Oncology Biology Physics, 2021, 111, S91.	0.4	1
41	Learning healthcare systems and rapid learning in radiation oncology: Where are we and where are we going?. Radiotherapy and Oncology, 2021, 164, 183-195.	0.3	9
42	Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013. International Journal of Radiation Oncology Biology Physics, 2021, 111, e468-e469.	0.4	0
43	Demystifying Cardiac Dose in RTOG-0617. International Journal of Radiation Oncology Biology Physics, 2021, 111, S125.	0.4	1
44	Prophylactic cranial irradiation (PCI), hippocampal avoidance (HA) whole brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in small cell lung cancer (SCLC): Where do we stand?. Lung Cancer, 2021, 162, 96-105.	0.9	17
45	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC: Update from PACIFIC. Journal of Thoracic Oncology, 2020, 15, 288-293.	0.5	328
46	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. Journal of Thoracic Oncology, 2020, 15, 216-230.	0.5	49
47	Multifactorial risk factors for mortality after chemotherapy and radiotherapy for non-small cell lung cancer. Radiotherapy and Oncology, 2020, 152, 117-125.	0.3	19
48	Is tumour sphericity an important prognostic factor in patients with lung cancer?. Radiotherapy and Oncology, 2020, 143, 73-80.	0.3	18
49	Distributed learning on 20 000+ lung cancer patients: The Personal Health Train. Radiotherapy and Oncology, 2020, 144, 189-200.	0.3	97
50	The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts. Radiotherapy and Oncology, 2020, 145, 45-48.	0.3	9
51	The impact of baseline shifts towards the heart after image guidance on survival in lung SABR patients. Radiotherapy and Oncology, 2020, 152, 183-188.	0.3	12
52	CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology, 2020, 25, 61-66.	0.9	15
53	Predictive value of vascular calcification identified in 4D planning CT of lung cancer patients treated with stereotactic body radiation therapy. Physica Medica, 2020, 78, 173-178.	0.4	5
54	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	1.3	81

#	ARTICLE	IF	CITATIONS
55	Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. <i>European Radiology</i> , 2020, 30, 6241-6250.	2.3	115
56	Impact of small residual setup errors after image guidance on heart dose and survival in non-small cell lung cancer treated with curative-intent radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 152, 177-182.	0.3	9
57	Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1073-1081.	0.4	62
58	Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype. <i>Lung Cancer</i> , 2020, 146, 197-208.	0.9	74
59	Less is more in radiotherapy target volume planning: lessons from the PET-plan trial. <i>Lancet Oncology</i> , The, 2020, 21, 481-483.	5.1	1
60	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.4	40
61	Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1624-1635.	0.5	89
62	ESTRO ACROP guidelines for target volume definition in the thoracic radiation treatment of small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 89-95.	0.3	23
63	Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1082-1090.	0.4	10
64	SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection. <i>European Respiratory Journal</i> , 2020, 56, 2000118.	3.1	27
65	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. <i>Practical Radiation Oncology</i> , 2020, 10, 158-173.	1.1	111
66	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.3	168
67	Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. <i>Radiotherapy and Oncology</i> , 2020, 149, 84-88.	0.3	13
68	Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e159-e170.	1.8	7
69	Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung cancer – Decision criteria in routine practise. <i>Radiotherapy and Oncology</i> , 2020, 150, 26-29.	0.3	13
70	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	0.6	50
71	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	3.1	151
72	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. <i>Annals of Translational Medicine</i> , 2020, 8, 1114.	0.7	0

#	ARTICLE	IF	CITATIONS
73	Radiotherapy tumor volume for limited-stage small cell lung cancer: less is more. <i>Annals of Translational Medicine</i> , 2020, 8, 1114-1114.	0.7	1
74	In Regard to Zhang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1179-1180.	0.4	6
75	Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer. <i>Acta Oncologica</i> , 2019, 58, 1378-1385.	0.8	24
76	Reply to G. Zalcman et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 2694-2695.	0.8	0
77	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
78	Recent developments in limited stage small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S147-S152.	1.3	17
79	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
80	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019, 136, 145-147.	0.9	17
81	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
82	Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer? In Reply. <i>JAMA Oncology</i> , 2019, 5, 1229.	3.4	1
83	Author's Reply to the: Letter to the Editor. <i>Journal of Thoracic Oncology</i> , 2019, 14, e63-e64.	0.5	0
84	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.3	53
85	18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1296-1305.	0.5	32
86	Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3818-3829.	3.2	51
87	Quantitative evaluation of 4D Cone beam CT scans with reduced scan time in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2019, 136, 64-70.	0.3	10
88	Influence of tumour laterality on patient survival in non-small cell lung cancer after radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 137, 71-76.	0.3	9
89	Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. <i>Annals of Oncology</i> , 2019, 30, 1114-1120.	0.6	54
90	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 135, 74-77.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 115-119.	0.3	42
92	The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance. <i>British Journal of Radiology</i> , 2019, 92, 20180988.	1.0	9
93	Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1200-1208.	0.8	52
94	Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study. <i>BMJ Open</i> , 2019, 9, e019903.	0.8	9
95	Cancers bronchiques de stade III: rôle de l'radiothérapie. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 278-289.	0.0	0
96	Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer Patients: Secondary Findings From the Prospective Randomized Phase 3 CONVERT Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 294-297.	0.5	17
97	Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 63-71.	0.5	37
98	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). <i>Annals of Oncology</i> , 2019, 30, 161-165.	0.6	60
99	The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). <i>Radiotherapy and Oncology</i> , 2019, 131, 166-173.	0.3	59
100	Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, e185335.	3.4	46
101	Letter to the Editor: Increasing PET Use in Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, xxxixb.	2.3	0
102	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
103	BTS guideline for the investigation and management of malignant pleural mesothelioma. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000266.	1.2	35
104	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. <i>Thorax</i> , 2018, 73, i1-i30.	2.7	157
105	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
106	A method to combine target volume data from 3D and 4D planned thoracic radiotherapy patient cohorts for machine learning applications. <i>Radiotherapy and Oncology</i> , 2018, 126, 355-361.	0.3	12
107	Benefit of using motion compensated reconstructions for reducing inter-observer and intra-observer contouring variation for organs at risk in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2018, 126, 333-338.	0.3	6
108	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018, 29, 301-310.	0.6	98

#	ARTICLE	IF	CITATIONS
109	ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 1-5.	0.3	141
110	Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 475-477.	0.5	5
111	Response to a Request for Clarification Regarding the Advanced Radiotherapy Technologies Network (ART-NET). <i>Clinical Oncology</i> , 2018, 30, 391-393.	0.6	0
112	Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2018, 110, 14-30.	3.0	177
113	A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. <i>Acta Oncologica</i> , 2018, 57, 226-230.	0.8	35
114	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	1.1	16
115	Results from a clinical trial evaluating the efficacy of real-time body surface visual feedback in reducing patient motion during lung cancer radiotherapy. <i>Acta Oncologica</i> , 2018, 57, 211-218.	0.8	4
116	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
117	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350.	13.9	2,150
118	ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. <i>European Respiratory Journal</i> , 2018, 52, 1800610.	3.1	8
119	Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 18-22.	0.7	3
120	Residual Setup Errors Towards the Heart After Image Guidance Linked With Poorer Survival in Lung Cancer Patients: Do We Need Stricter IGRT Protocols?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 434-442.	0.4	39
121	Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. <i>British Journal of Cancer</i> , 2018, 119, 389-407.	2.9	92
122	The use of volunteers to implement electronic patient reported outcomes in lung cancer outpatient clinics. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2018, 7, 11-16.	0.6	2
123	Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1057-1060.	0.4	83
124	Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. <i>BMJ Open</i> , 2018, 8, e020690.	0.8	56
125	Clinical guidelines on diagnosis and management of patients with malignant pleural mesothelioma (part 1). <i>Pulmonology</i> , 2018, 28, 531-557.	0.2	0
126	Whole brain radiotherapy for non-small cell lung cancer - Authors' reply. <i>Lancet</i> , 2017, 389, 1395-1396.	6.3	2

#	ARTICLE	IF	CITATIONS
127	Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer. Expert Review of Anticancer Therapy, 2017, 17, 555-561.	1.1	8
128	Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial. Lung Cancer, 2017, 108, 150-153.	0.9	70
129	Developing and Validating a Survival Prediction Model for NSCLC Patients Through Distributed Learning Across 3 Countries. International Journal of Radiation Oncology Biology Physics, 2017, 99, 344-352.	0.4	102
130	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncology, The, 2017, 18, 1116-1125.	5.1	415
131	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	0.5	40
132	MTE05.01 Where is the Place of Surgery for N2 Disease?. Journal of Thoracic Oncology, 2017, 12, S152-S154.	0.5	0
133	P2.05-058 Blood Biomarkers of Inflammation, Tumor Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1067-S1068.	0.5	0
134	OA05.06 Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial. Journal of Thoracic Oncology, 2017, 12, S262-S263.	0.5	1
135	OA05.07 Prognostic Value of Circulating Tumor Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial. Journal of Thoracic Oncology, 2017, 12, S263.	0.5	2
136	MA13.11 Investigating the Feasibility of Establishing a Prospective Cohort of Lung Cancer Patients Following Radiotherapy with Curative Intent. Journal of Thoracic Oncology, 2017, 12, S421.	0.5	0
137	Effect of accurate heart delineation on cardiac dose during the CONVERT trial. British Journal of Radiology, 2017, 90, 20170036.	1.0	8
138	Management of stage I and II nonsmall cell lung cancer. European Respiratory Journal, 2017, 49, 1600764.	3.1	56
139	Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer. Radiotherapy and Oncology, 2017, 122, 159-162.	0.3	6
140	Is it time to convert the frequency of radiotherapy in small-cell lung cancer? " Authors' reply. Lancet Oncology, The, 2017, 18, e556.	5.1	4
141	The CONVERT Trial: Interpretation, Journey and Lessons Learnt. Clinical Oncology, 2017, 29, 811-813.	0.6	6
142	Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. Annals of Oncology, 2017, 28, 2923-2931.	0.6	46
143	Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET). Clinical Oncology, 2017, 29, 707-710.	0.6	12
144	Radiation dose to heart base linked with poorer survival in lung cancer patients. European Journal of Cancer, 2017, 85, 106-113.	1.3	136

#	ARTICLE	IF	CITATIONS
145	A multi-centre dosimetry audit on advanced radiotherapy in lung as part of the Isotoxic IMRT study. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 4, 17-21.	1.2	7
146	CONVERTed or not: what are the barriers to implementing the evidence? – Author's reply. <i>Lancet Oncology</i> , The, 2017, 18, e628.	5.1	2
147	European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 1-10.	0.3	177
148	Breaking the Glass Ceiling for Women in Academic Clinical Oncology in the UK: A Personal View. <i>Clinical Oncology</i> , 2017, 29, 1-2.	0.6	5
149	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	12.5	792
150	R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. <i>Frontiers in Oncology</i> , 2017, 7, 59.	1.3	90
151	The clinical utility of circulating tumour cells in patients with small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 409-417.	1.3	28
152	Magnetic resonance imaging in precision radiation therapy for lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 689-707.	1.3	56
153	How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?. <i>Translational Cancer Research</i> , 2017, 6, S446-S447.	0.4	0
154	Protocol for the CONVERT trial – Concurrent ONce-daily VErus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMJ Open</i> , 2016, 6, e009849.	0.8	37
155	Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. <i>BMJ Open</i> , 2016, 6, e010457.	0.8	24
156	Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. <i>Lancet</i> , The, 2016, 388, 2004-2014.	6.3	556
157	OC-0257: A Bayesian network model for acute dysphagia prediction in the clinic for NSCLC patients. <i>Radiotherapy and Oncology</i> , 2016, 119, S118-S119.	0.3	0
158	Data Mining Identifies the Base of the Heart as a Dose-Sensitive Region Affecting Survival in Lung Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, S48-S49.	0.4	14
159	Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. <i>BMJ Open</i> , 2016, 6, e010589.	0.8	28
160	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1627-1643.	0.5	67
161	CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8504-8504.	0.8	24
162	PO-0656: Effect of accurate heart outlining on radiation dose to the heart - the CONVERT Trial experience. <i>Radiotherapy and Oncology</i> , 2015, 115, S319-S320.	0.3	0

#	ARTICLE	IF	CITATIONS
163	EP-1527: Early results from a clinical trial of visual feedback from dynamic optical surface sensing in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2015, 115, S833-S834.	0.3	0
164	Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. <i>Annals of Oncology</i> , 2015, 26, 278-288.	0.6	27
165	In Regard to Koshy et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 945-946.	0.4	5
166	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. <i>EBioMedicine</i> , 2015, 2, 841-850.	2.7	24
167	Dose escalation in lung cancer: have we gone full circle?. <i>Lancet Oncology</i> , The, 2015, 16, 125-127.	5.1	30
168	PO-0660: A survey of current lung radiotherapy treatment techniques used during the CONVERT Trial. <i>Radiotherapy and Oncology</i> , 2015, 115, S321-S322.	0.3	0
169	PO-1119 Suitability of lung margins following analysis of set up data within a multi-national lung trial. <i>Radiotherapy and Oncology</i> , 2015, 115, S606-S607.	0.3	0
170	LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. <i>British Journal of Radiology</i> , 2015, 88, 20150036.	1.0	96
171	Radiotherapy for extensive stage small-cell lung cancer – Authors' reply. <i>Lancet</i> , The, 2015, 385, 1292-1293.	6.3	38
172	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	0.6	308
173	Postoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized Evidence. <i>Journal of Clinical Oncology</i> , 2015, 33, 2930-2931.	0.8	15
174	PO-0663: Lung V5 does not predict for lung toxicity after fixed-beam intensity modulated radiotherapy (IMRT) for lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, S323-S324.	0.3	0
175	Stereotactic body radiotherapy for central lung tumours: Author reply. <i>British Journal of Radiology</i> , 2015, 88, 20150532.	1.0	0
176	Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 385, 36-42.	6.3	441
177	Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8005-8005.	0.8	17
178	Outcomes of Elderly Patients (≥70 Yo) with Advanced Non-Small Cell Lung Cancer (Nslc): a Multi-Institutional Analysis. <i>Annals of Oncology</i> , 2014, 25, iv442.	0.6	0
179	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	105
180	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	0.6	210

#	ARTICLE	IF	CITATIONS
181	High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2014, 15, e620-e624.	5.1	76
182	Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1598-1608.	0.5	63
183	The European initiative for quality management in lung cancer care. <i>European Respiratory Journal</i> , 2014, 43, 1254-1277.	3.1	44
184	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	0.6	246
185	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. <i>Lung Cancer</i> , 2014, 83, 117-125.	0.9	35
186	New radiotherapy approaches in locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2014, 50, 525-534.	1.3	43
187	Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 682-693.	3.3	39
188	Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. <i>Annals of Oncology</i> , 2014, 25, 1270-1283.	0.6	147
189	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	0.6	410
190	Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 244-249.	0.3	25
191	Cancers bronchiques non À petites cellules localement avancÃ©s : quelle radiothÃ©rapie en 2014 ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 421-430.	0.0	0
192	Traditional Phase 1 and 2 Studies in Thoracic Radiation Oncology Should Be Abandoned. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 487-489.	0.4	13
193	Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer. <i>British Journal of Radiology</i> , 2014, 87, 20130653.	1.0	14
194	International Multicenter Randomized Study on Thoracic Radiation Therapy (RT) in Extensive Stage Small Cell Lung Cancer (ES-SCLC): Patterns of Disease Recurrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S3-S4.	0.4	2
195	Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2014, 6, 328-35.	0.6	16
196	Stereotactic body radiotherapy (SBRT) in central non-small cell lung cancer (NSCLC): Solid evidence or "œno-goâ€?. <i>Radiotherapy and Oncology</i> , 2013, 109, 178-179.	0.3	16
197	Radical treatment of non-small cell lung cancer during the last 5 years. <i>European Journal of Cancer</i> , 2013, 49, 1555-1564.	1.3	54
198	Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with Stage I non-small-cell lung cancer?: Table 1:. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013, 17, 845-853.	0.5	26

#	ARTICLE	IF	CITATIONS
199	Improving care for patients with lung cancer in the UK. Thorax, 2013, 68, 1181-1185.	2.7	10
200	Treatment of Limited-Stage Disease in Older Patients: The Role of Thoracic Radiotherapy and Prophylactic Cranial Irradiation. , 2013, , 223-232.		0
201	Efficacy of Positron Emission Tomography Staging for Small-Cell Lung Cancer: A Systematic Review and Cost Analysis in the Australian Setting. Journal of Thoracic Oncology, 2012, 7, e25.	0.5	0
202	Management of Small Cell Lung Cancer. Drugs, 2012, 72, 471-490.	4.9	63
203	Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future. European Journal of Cancer, Supplement, 2012, 10, 99-104.	2.2	0
204	Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treatment Reviews, 2012, 38, 626-640.	3.4	76
205	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer " Evidence from a phase II trial. Lung Cancer, 2012, 76, 72-77.	0.9	39
206	Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer, 2012, 77, 532-536.	0.9	8
207	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. Lung Cancer, 2011, 73, 338-344.	0.9	4
208	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer, 2011, 74, 75-9.	0.9	17
209	Treatment of limited small cell lung cancer: an old or new challenge?. Current Opinion in Oncology, 2011, 23, 158-162.	1.1	9
210	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 2011, 22, 1154-1163.	0.6	165
211	Guidelines on the radical management of patients with lung cancer. Thorax, 2010, 65, iii1-iii27.	2.7	393
212	European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5301-5310.	0.8	276
213	Radiotherapy for lung cancer in the elderly. Lung Cancer, 2010, 68, 129-136.	0.9	34
214	Lung cancer after treatment for breast cancer. Lancet Oncology, The, 2010, 11, 1184-1192.	5.1	30
215	ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and) Tj ETQq1 1 0.784314 rgBT /Overlock 101	3.1	756
216	The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. European Journal of Cardio-thoracic Surgery, 2009, 36, 181-184.	0.6	114

#	ARTICLE	IF	CITATIONS
217	Lung function evaluation before surgery in lung cancer patients: how are recent advances put into practice? A survey among members of the European Society of Thoracic Surgeons (ESTS) and of the Thoracic Oncology Section of the European Respiratory Society (ERS). <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2009, 9, 925-931.	0.5	33
218	Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptomsâ€”Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups. <i>Journal of Clinical Oncology</i> , 2009, 27, 73-84.	0.8	240
219	VARELA, M. LICKER, M.K. FERGLISON, C. FAIVRE-FINN, R.M. HUBER, E.M. CLINI, T. WIN, D. DE RUIYSSCHER AND L. GOLDMAN ON BEHALF OF THE EUROPEAN RESPIRATORY SOCIETY AND EUROPEAN SOCIETY OF THORACIC SURGEONS JOINT TASK FORCE ON FITNESS FOR RADICAL THERAPY. <i>EUR RESPIR J</i> 2009; 34: 17-41.. <i>European Respiratory Journal</i> , 2009, 34, 782-782.	3.1	25
220	Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. <i>Lung Cancer</i> , 2009, 66, 150-156.	0.9	58
221	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01). <i>Tj ETQq1 1 0,784314,rgBT /Over</i> 10, 467-474.	5.1	318
222	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 442-447.	2.9	43
223	Management of Unresectable Stage III Nonâ€”Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment. <i>Clinical Lung Cancer</i> , 2008, 9, 92-101.	1.1	24
224	B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration. <i>Journal of Thoracic Oncology</i> , 2007, 2, S338.	0.5	2
225	Small Cell Lung Cancer (SCLC); any progress?. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 398-399.	2.2	0
226	Modern Management of Small-Cell Lung Cancer. <i>Drugs</i> , 2007, 67, 2135-2152.	4.9	37
227	Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2007, 357, 664-672.	13.9	990
228	D1-01: Prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer (ED-SCLC) after response to chemotherapy (EORTC 08993-22993): Quality of life (QoL) results.. <i>Journal of Thoracic Oncology</i> , 2007, 2, S389.	0.5	1
229	Respiratory Intrafraction Motion is an Important Source of Error in Radiotherapy to Oesophago-gastric Junction (OGJ) Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S280.	0.4	0
230	D1-02: Initial results from an intergroup phase III trial evaluating two different doses of prophylactic cranial irradiation (PCI) in patients with limited small cell cancer (SCLC) in complete remission (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212). <i>Journal of Thoracic Oncology</i> , 2007, 2, S389-S390.	0.5	1
231	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5051s-5056s.	3.2	9
232	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 41-50.	2.2	0
233	Thoracic Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Unanswered Questions. <i>Clinical Lung Cancer</i> , 2005, 7, 23-29.	1.1	22
234	O-90 Randomised phase III trial of docetaxel/carboplatin vs. MIC/MVP chemotherapy in inoperable advanced non-small cell lung cancer (NSCLC) â€” A British thoracic oncology group (BTOG) trial. <i>Lung Cancer</i> , 2003, 41, S29.	0.9	1

#	ARTICLE	IF	CITATIONS
235	Colon cancer in France: evidence for improvement in management and survival. <i>Gut</i> , 2002, 51, 60-64.	6.1	115
236	Effect of age, period of diagnosis and birth cohort on large bowel cancer incidence in a well-defined French population, 1976-1995. <i>European Journal of Cancer Prevention</i> , 2002, 11, 529-534.	0.6	24
237	Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 353-359.	1.9	37
238	Colorectal adenocarcinoma in patients under 45 years of age. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 380-387.	0.7	92
239	Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. <i>Radiotherapy and Oncology</i> , 2000, 57, 137-142.	0.3	18
240	Evidence of improving survival of patients with rectal cancer in France: a population based study. <i>Gut</i> , 1999, 44, 377-381.	6.1	49
241	Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 25-38.	0.4	240
242	Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. <i>Journal of Hepatology</i> , 1998, 29, 802-806.	1.8	57
243	Impact of Introducing Intensity Modulated Radiotherapy on Curative Intent Radiotherapy and Survival for Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3